Your NCI: Top Priorities from AACR 2026

Research news: In a May 4, 2026 Cancer Currents post, NCI Director Anthony Letai summarized scientific themes and program priorities highlighted at AACR 2026 (San Diego, April 19–22). He pointed to ongoing questions in immuno-oncology response variability, growing momentum in cancer therapeutic vaccines (with NCI–FNIH partnership planning multiple trials), advances and standardization needs in functional precision medicine, and the push for shared, interoperable AI tools. NCI also emphasized streamlining early-phase trials, prevention/access, and human-based models.

Your NCI: Top Priorities from AACR 2026 (research news)

In a May 4, 2026 Cancer Currents post, NCI Director Anthony Letai, MD, PhD, reflected on themes from the AACR Annual Meeting 2026 (San Diego, April 19–22), describing areas he expects to shape NCI’s work.

Scientific areas highlighted

  • Immuno-oncology: Letai noted meaningful success with immune checkpoint inhibitors and cellular therapies, while underscoring unresolved questions about why responses vary and how to translate emerging insights into more consistent benefit. He described discussions as “far from settled.”
  • Cancer therapeutic vaccines: He said vaccine research is gaining momentum, citing early research suggesting vaccines could help prevent recurrence, particularly in cancers with common relapse. NCI, with the Foundation for the NIH, is “targeted” to unveil later in 2026 a plan for multiple structured trials to evaluate therapeutic vaccine approaches.
  • Functional precision medicine: Letai highlighted interest in testing drugs directly on a patient’s tumor cells, with AACR presentations suggesting new technologies and data increasingly support this approach. He said next steps include defining reliability and enabling broader use; NCI plans a community workshop in summer 2026.
  • Artificial intelligence: He emphasized moving beyond tool creation toward sharing and interoperability across systems.

Program priorities

Letai also cited priorities to improve efficiency of (especially early-phase) clinical trials, strengthen prevention and access via the Prevention, Screening, and Early Detection Initiative (PSEDI; early planning), and expand use of human-based models alongside animal models.

Sources